Many recent Alzheimer disease trials focus on anti-amyloid interventions and hence require evidence of amyloidosis for inclusion.37,59,60,61 However, as trials become increasingly sophisticated in targeting specific Alzheimer disease pathogenic pathways, information about both amyloid and tau status will be needed. This evidence concerns the gene MAPT and amyloidosis.